Vensana Capital
SelectiveFiled to raiseMinneapolis, MNHealthcare, BiotechnologyLast fund filed 2024
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Vensana Capital IIIFiled to raise in 2024, with no closing reported yet. | 2024 | $425M | $0 | 0 |
| Vensana Capital IIFiled to raise in 2021, with no closing reported yet. | 2021 | $300M | $0 | 0 |
| VMT Fund IFiled to raise in 2018, with no closing reported yet. | 2018 | $200M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kirk Nielsen | Selective | Medical devices, Biotech & pharma, Digital health | 18 | 3 |
| Peter Klein | Quiet | Medical devices, Biotech & pharma, Logistics & supply chain | 16 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Vensana Capital’s own portfolio companies, based on 33 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Vensana Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Venture Capital | 19 | Alleviant Medical, Artelon, Ceterix Orthopaedics, CVRx, HOLAIRA, Inari Medical, iVEAcare, Metavention, Monteris Medical US, Moxe Health, NEUWAVE MEDICAL, Okami Medical, Rampart IC, Relievant MedSystems, Respicardia, Sequent Medical, SpyGlass Ophthalmics, VI1, ZYGA TECHNOLOGY |
| NEA | 4 | Ceterix Orthopaedics, Intact Vascular, Senseonics Holdings, Senseonics |
| Domain Partners | 3 | ChromaCode, Sequent Medical, ZYGA TECHNOLOGY |
| Tier One Associates | 3 | Inari Medical, Okami Medical, Sequent Medical |
| U.S Venture Partners | 3 | Inari Medical, Okami Medical, Sequent Medical |
| Treo Ventures | 2 | CVRx, iVEAcare |
| AI2 Incubator | 1 | Apptio |
| Astoria Health Investors | 1 | SpyGlass Ophthalmics |
| Camber Creek | 1 | Alleviant Medical |
| Frist Cressey Ventures | 1 | Accolade |
| Grayhawk | 1 | Alleviant Medical |
| Hatteras Venture Partners | 1 | iVEAcare |
| LRVHealth | 1 | Cleerly |
| Madrona Venture Group | 1 | Apptio |
| New Leaf | 1 | Cleerly |
A shared board seat: a company where filings name a Vensana Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.